- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06526195
Ensaio para avaliar a segurança e eficácia do suporte circulatório mecânico em pacientes com insuficiência cardíaca avançada (TEAM-HF)
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
Visão geral do estudo
Status
Descrição detalhada
Patients with heart failure (HF) suffer from a high degree of morbidity and mortality. Left ventricular assist device (LVAD) therapy has become the standard of care for the treatment of advanced HF patients who are deemed to be dependent on continuous intravenous inotropes, extending life expectancy, enhancing overall quality of life, and improving functional capacity. However, use of LVADs in ambulatory, non-inotrope dependent advanced HF population is limited. Elevated mean pulmonary artery pressure (PAP) secondary to left ventricular failure has emerged as a potential predictor of increased mortality risk for patients refractory to maximally tolerated guideline directed medical therapy (GDMT). In these patients, left ventricular failure with elevated mean PAP may represent objective criteria to identify advanced HF patients requiring heart replacement therapies such as LVAD.
The TEAM-HF IDE trial will enroll approximately 850 subjects with New York Heart Association (NYHA) Class IIIB/IV HF who had a prior heart failure hospitalization and an elevated mean PAP secondary to left ventricular failure. Elevated mean PAP will be identified using an implanted PAP monitoring sensor, the CardioMEMS PA Sensor. All subjects enrolled can have a previously implanted CardioMEMS PA Sensor or, if not, will be implanted with the CardioMEMS PA Sensor after enrollment. The overall objectives of TEAM-HF trial are two-fold: 1) To determine whether PAP can objectively identify patients most at risk for worsening HF and therefore most likely to benefit from earlier intervention with LVAD therapy and 2) To determine the benefit of LVAD therapy in non-inotrope advanced HF patients with elevated mean PAP refractory to GDMT.
The trial will include approximately 75 global sites and consists of a Randomized Arm and a Single Arm Registry.
The TEAM-HF Randomized Arm is a prospective, randomized, open-label study of the HeartMate 3 (HM3) left ventricular assist system (LVAS) versus continued GDMT in non-inotrope dependent HF patients. The objectives of the Randomized Arm are 1) To establish an objective disease-state criteria to trigger referral for a HM3 LVAS and 2) Demonstrate improvement in survival when non-inotrope dependent advanced HF patients are treated with the HM3 LVAS compared to being managed on medical therapy alone.
The TEAM-HF Single Arm Registry is a prospective, single-arm, open-label study of non-inotrope dependent HF patients who do not meet a mean PAP threshold after GDMT optimization. The objective of the Single Arm Registry is to characterize the progression of patients with non-inotrope dependent HF without elevated PAP.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Nourdine Chakouri, PhD
- Número de telefone: 925-989-5982
- E-mail: nourdine.chakouri@abbott.com
Locais de estudo
-
-
Saxon
-
Hanover, Saxon, Alemanha, 30625
- Recrutamento
- Medizinische Hochschule Hannover
-
Investigador principal:
- Dominik Berliner, MD
-
Contato:
- Antje Juergens
- Número de telefone: +49-0115-323-1113
- E-mail: juergens.antje@mh-hannover.de
-
-
Saxony
-
Leipzig, Saxony, Alemanha, 04289
- Recrutamento
- Herzzentrum Leipzig GmbH
-
Investigador principal:
- Michael Borger, MD
-
Contato:
- Victoria Himstedt
- Número de telefone: +49 341 865 25
- E-mail: victoria.himstedt@helios-health-institute.com
-
-
State of Berlin
-
Berlin, State of Berlin, Alemanha, 13353
- Recrutamento
- Deutsches Herzzentrum der Charité
-
Investigador principal:
- Felix Schoenrath, MD
-
Contato:
- Annegret Schneider
- Número de telefone: +49-304-593-2303
- E-mail: schneider@dhzb.de
-
-
-
-
Riyadh Region
-
Riyadh, Riyadh Region, Arábia Saudita, 11525
- Recrutamento
- King Fahad Medical City
-
Investigador principal:
- Mohammed Alreshidan, MD
-
Contato:
- Joud Hewaidi
- Número de telefone: +966-530003751
- E-mail: jhewaidi@kfmc.med.sa
-
Riyadh, Riyadh Region, Arábia Saudita, 12713
- Recrutamento
- King Faisal Specialist Hospital
-
Contato:
- Luluah Altukhaifi
- Número de telefone: +966 0556481098
- E-mail: laltukaifi@kfshrc.edu.sa
-
Investigador principal:
- Jehad Abdulhamid Al Buraiki, MD
-
-
-
-
Copenhagen
-
Copenhagen, Copenhagen, Dinamarca, 2100
- Recrutamento
- Rigshospitalet
-
Contato:
- Christina Moeller
- Número de telefone: +00 453 545 6757
- E-mail: Christina.Moeller@regionh.dk
-
Investigador principal:
- Kasper Rossing, MD
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85006
- Retirado
- Banner-University Medical Center Phoenix
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Recrutamento
- Baptist Health Medical Center
-
Investigador principal:
- Patrick Campbell, MD
-
Contato:
- Victoria Marren
- Número de telefone: 678-654-0327
- E-mail: victoria.marren@baptist-health.org
-
-
California
-
Sacramento, California, Estados Unidos, 95816
- Recrutamento
- Sutter Medical Center
-
Contato:
- Jessica Mccall
- Número de telefone: 916-887-4654
- E-mail: jessica.mccall@sutterhealth.org
-
Investigador principal:
- Michael Gibson, MD
-
San Francisco, California, Estados Unidos, 94143
- Recrutamento
- University of California at San Francisco
-
Contato:
- Tyre Richardson
- Número de telefone: (209) 650-5302
- E-mail: tyre.richardson@ucsf.edu
-
Investigador principal:
- Shweta Motiwala, MD
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- Recrutamento
- Washington Hospital Center
-
Investigador principal:
- Sheikh Farooq, MD
-
Contato:
- Hellina Birru
- Número de telefone: 202-877-6334
- E-mail: hellina.t.birru@medstar.net
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610
- Recrutamento
- Shands at the University of Florida
-
Investigador principal:
- Mustafa Ahmed, MD
-
Contato:
- Erikson Walter
- Número de telefone: 269-331-9581
- E-mail: erikson.walter@ufl.edu
-
Weston, Florida, Estados Unidos, 33331
- Recrutamento
- Cleveland Clinic Florida
-
Contato:
- Maria Mejia-Gomez
- Número de telefone: 954-659-5888
- E-mail: mejiagm@ccf.org
-
Investigador principal:
- Mauricio Velez, MD
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30309
- Recrutamento
- Piedmont Heart Institute
-
Investigador principal:
- Catherine Marti, MD
-
Contato:
- Andrew Bailey
- Número de telefone: 404-605-4098
- E-mail: Andrew.Bailey1@piedmont.org
-
Augusta, Georgia, Estados Unidos, 30901
- Recrutamento
- Piedmont Augusta Hospital
-
Investigador principal:
- Darshak Karia, MD
-
Contato:
- Jennifer Hansen
- Número de telefone: 706-724-2463
- E-mail: jennifer.hansen@piedmont.org
-
Marietta, Georgia, Estados Unidos, 30060
- Recrutamento
- WellStar Kennestone Hospital
-
Investigador principal:
- Abdul Bikak, MD
-
Contato:
- Amuthanayaki Kanagaraj
- Número de telefone: 470-793-7554
- E-mail: amuthanayaki.kanagaraj2@wellstar.org
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Recrutamento
- University of Chicago
-
Contato:
- Kristen Hanauer
- Número de telefone: 773-702-8716
- E-mail: kristen.hanauer@bsd.uchicago.edu
-
Investigador principal:
- Nikhil Narang, MD
-
Oakbrook Terrace, Illinois, Estados Unidos, 60181
- Recrutamento
- Advocate Health & Hospitals Corporation
-
Contato:
- Mairead Delaney
- Número de telefone: 708-684-4209
- E-mail: mairead.delaney@aah.org
-
Investigador principal:
- Vinh Chau, MD
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46240
- Recrutamento
- St. Vincent Hospital
-
Investigador principal:
- Ashwin Ravichandran, MD
-
Contato:
- Regina Margiotti
- Número de telefone: 317-338-6151
- E-mail: Regina.Margiotti@ascension.org
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Recrutamento
- University of Iowa Hospitals & Clinics
-
Contato:
- Page Scovel
- Número de telefone: 319- 356-2585
- E-mail: Page-scovel@uiowa.edu
-
Investigador principal:
- Anthony Panos, MD
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Recrutamento
- Kansas University Medical Center
-
Contato:
- Terry Christenson
- Número de telefone: 515-210-2626
- E-mail: tchristenson3@kumc.edu
-
Investigador principal:
- Zubair Shah, MD
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- Rescindido
- University of Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- Recrutamento
- Norton Hospital
-
Contato:
- Laurie Michelle Jones
- Número de telefone: 502-891-8699
- E-mail: laurie.jones@nortonhealthcare.org
-
Investigador principal:
- Alkhalil Bassel, MD
-
-
Maine
-
Portland, Maine, Estados Unidos, 04102
- Recrutamento
- Maine Medical Center
-
Contato:
- Monica Palmeri
- Número de telefone: 207-662-2090
- E-mail: monica.palmeri@mainehealth.org
-
Investigador principal:
- Peter Kennel, MD
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Recrutamento
- Massachusetts General Hospital
-
Contato:
- Bronwen Rees-Weidemann
- Número de telefone: 617-726-5508
- E-mail: brees-wiedemann@mgh.harvard.edu
-
Investigador principal:
- Erin Coglianese, MD
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Recrutamento
- Henry Ford Hospital
-
Contato:
- Zack Malouf
- Número de telefone: 313-585-7068
- E-mail: zmalouf1@hfhs.org
-
Investigador principal:
- Lindsey Aurora, MD
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Recrutamento
- Spectrum Health Butterworth Hospital
-
Contato:
- Stephanie Hanson
- Número de telefone: 616-391-0284
- E-mail: stephanie.hanson@corewellhealth.org
-
Investigador principal:
- Matthew Gonzalez, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Recrutamento
- Minneapolis Heart Institute
-
Investigador principal:
- Mosi Bennett, MD
-
Contato:
- Kate Jappe
- Número de telefone: 612-863-7347
- E-mail: Kate.Jappe@allina.com
-
Rochester, Minnesota, Estados Unidos, 55905
- Recrutamento
- Mayo Clinic
-
Contato:
- Colleen Irlbeck
- Número de telefone: 507-266-6879
- E-mail: Irlbeck.Colleen@mayo.edu
-
Investigador principal:
- Andrew Rosenbaum, MD
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- Recrutamento
- St. Luke's Hospital
-
Investigador principal:
- Timothy Fendler, MD
-
Contato:
- Amanda Huffman
- Número de telefone: 816-932-0391
- E-mail: ahuffman@saint-lukes.org
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198
- Recrutamento
- University of Nebraska Medical Center
-
Contato:
- Ryan Ruskamp
- Número de telefone: 402-836-9779
- E-mail: ryan.ruskamp@unmc.edu
-
Investigador principal:
- Adam Burdorf, DO
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Recrutamento
- Hackensack University Medical Center
-
Investigador principal:
- Kanika Mody, MD
-
Contato:
- Manuel Castillo
- Número de telefone: 551-996-2136
- E-mail: Manuel.Castillo@hmhn.org
-
Newark, New Jersey, Estados Unidos, 07112
- Recrutamento
- Newark Beth Israel Medical Center
-
Investigador principal:
- Igor Gosev, MD
-
Contato:
- Patel Bhargavi
- Número de telefone: 516-600-1487
- E-mail: bhargavi.patel2@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87102
- Recrutamento
- New Mexico Heart Institute
-
Contato:
- Rebecca Jones
- Número de telefone: 505-843-2827
- E-mail: Rebecca.Jones@lovelace.com
-
Investigador principal:
- Dana Booth, MD
-
-
New York
-
Manhasset, New York, Estados Unidos, 11030
- Recrutamento
- North Shore University Hospital
-
Contato:
- Salome Reddy
- Número de telefone: 516-600-1459
- E-mail: seliareddy@northwell.edu
-
Investigador principal:
- Maria Avila, MD
-
New York, New York, Estados Unidos, 10032
- Recrutamento
- New York-Presbyterian/Columbia University Medical Center
-
Contato:
- Jessica Idumonyi
- Número de telefone: 212-305-1368
- E-mail: joi2102@cumc.columbia.edu
-
Investigador principal:
- Dor Lotan, MD
-
Rochester, New York, Estados Unidos, 14642
- Recrutamento
- University of Rochester Medical Center
-
Contato:
- Lori Caufield
- Número de telefone: (585) 273-4956
- E-mail: lori_caufield@urmc.rochester.edu
-
Investigador principal:
- Leway Chen, MD
-
The Bronx, New York, Estados Unidos, 10467
- Recrutamento
- Montefiore Medical Center - Moses Campus
-
Investigador principal:
- Yogita Rochlani, MD
-
Contato:
- Sabrina Sicilia
- E-mail: ssicilia@montefiore.org
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- Recrutamento
- University of North Carolina at Chapel Hill
-
Contato:
- Hanna Mixon
- Número de telefone: (919) 962-4896
- E-mail: hanna_mixon@med.unc.edu
-
Investigador principal:
- William Mostertz, MD
-
Charlotte, North Carolina, Estados Unidos, 28203
- Recrutamento
- Carolinas Medical Center
-
Contato:
- Dana Amaro
- Número de telefone: 704-355-4794
- E-mail: dana.amaro@atriumhealth.org
-
Investigador principal:
- Joseph Mishkin, MD
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Recrutamento
- Christ Hospital
-
Contato:
- Susanne Pasley
- Número de telefone: 513-585-1777
- E-mail: susanne.pasley@thechristhospital.com
-
Investigador principal:
- Emani Sitaramesh, MD
-
Cleveland, Ohio, Estados Unidos, 44195
- Recrutamento
- The Cleveland Clinic Foundation
-
Contato:
- Barbara Gus
- Número de telefone: 216-445-6552
- E-mail: gusb@ccf.org
-
Investigador principal:
- Michael Tong, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73112
- Recrutamento
- Integris Baptist Medical Center
-
Contato:
- Jill Bethany Fife
- Número de telefone: (405) 951-8607
- E-mail: bethany.fife@integrishealth.org
-
Investigador principal:
- Luke Cunningham, MD
-
Tulsa, Oklahoma, Estados Unidos, 74104
- Recrutamento
- Oklahoma Heart Institute at Utica
-
Contato:
- Allyson O'Guin
- Número de telefone: (918) 574-9253
- E-mail: allyson.oguin@hillcrest.com
-
Investigador principal:
- Luis David Meggo Quiroz, MD
-
Tulsa, Oklahoma, Estados Unidos, 74136
- Recrutamento
- Saint Francis Hospital
-
Investigador principal:
- Douglas Ensley, MD
-
Contato:
- Riley Pritzlaff
- Número de telefone: 918-494-8500
- E-mail: rpritzlaff@saintfrancis.com
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Recrutamento
- Oregon Health & Science University
-
Investigador principal:
- Johannes Steiner, MD
-
Contato:
- Ricardo Mendoza
- Número de telefone: (503) 494-9511
- E-mail: Mendozri@ohsu.edu
-
-
Pennsylvania
-
Abington, Pennsylvania, Estados Unidos, 19001
- Recrutamento
- Abington Memorial Hospital
-
Contato:
- Colleen Marchand
- Número de telefone: 215-481-4661
- E-mail: colleen.marchand@jefferson.edu
-
Investigador principal:
- Alexander Shpilman, MD
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Recrutamento
- Penn State Milton S. Hershey Medical Center
-
Investigador principal:
- John Boehmer, MD
-
Contato:
- Amanda Donnangelo
- Número de telefone: 717-531-0850
- E-mail: adonnangelo@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- University of Pennsylvania
-
Contato:
- Emma Markley
- Número de telefone: 585-273-3760
- E-mail: Emma.markley@pennmedicine.upenn.edu
-
Investigador principal:
- Himabindu Vidula, MD
-
Philadelphia, Pennsylvania, Estados Unidos, 15213
- Recrutamento
- University of Pittsburgh Medical Center (UPMC)
-
Investigador principal:
- Gavin Hickey, MD
-
Contato:
- Abbey Sung
- Número de telefone: 412-648-6024
- E-mail: sunga3@upmc.edu
-
Pittsburgh, Pennsylvania, Estados Unidos, 15212
- Recrutamento
- Allegheny General Hospital
-
Investigador principal:
- Matthew Lander, MD
-
Contato:
- Laurie Machen
- Número de telefone: 412-359-6181
- E-mail: Laurie.MACHEN@ahn.org
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Recrutamento
- Medical University of South Carolina
-
Investigador principal:
- Arman Kilic, MD
-
Contato:
- Melissa Lamicq
- Número de telefone: 954-683-4648
- E-mail: Lamicq@musc.edu
-
Columbia, South Carolina, Estados Unidos, 29203
- Recrutamento
- Prisma Health Midlands
-
Contato:
- Brooks Ferguson
- Número de telefone: 843-442-0994
- E-mail: Brooks.Ferguson@prismahealth.org
-
Investigador principal:
- James Ampadu, MD
-
Contato:
- Abigail Anderson
- Número de telefone: 864-455-7629
- E-mail: Abigail.Anderson@prismahealth.org
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38120
- Recrutamento
- The Stern Cardiovascular Foundation
-
Contato:
- Rishi Bhula
- Número de telefone: 901-271-2220
- E-mail: rishi.bhula@sterncardio.com
-
Investigador principal:
- Todd Edwards, MD
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- Recrutamento
- Ascension Texas Cardiovascular
-
Contato:
- Jennifer Mcsorley
- Número de telefone: 702-427-2014
- E-mail: jennifer.mcsorley@ascension.org
-
Investigador principal:
- Raymond Bietry, MD
-
Dallas, Texas, Estados Unidos, 75246
- Recrutamento
- Baylor University Hospital
-
Contato:
- Shelby Shull
- Número de telefone: 214-818-2587
- E-mail: Shelby.Shull@BSWHealth.org
-
Investigador principal:
- Cesar Guerrero-Miranda, MD
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Houston Methodist
-
Contato:
- Mary Kelly
- Número de telefone: (346) 238-8240
- E-mail: makelly@houstonmethodist.org
-
Investigador principal:
- Cindy Martin, MD
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- CHI St. Luke's Health Baylor College of Medicine Medical Center
-
Investigador principal:
- Ajith Nair, MD
-
Contato:
- Wajeeha Abrar
- Número de telefone: (713) 798-5404
- E-mail: Wajeeha.Abrar@bcm.edu
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- UTHealth Memorial Hermann
-
Contato:
- Lawana Self
- Número de telefone: 713-486-6751
- E-mail: lawana.self@uth.tmc.edu
-
Investigador principal:
- Nathan Sriram, MD
-
Plano, Texas, Estados Unidos, 75093
- Recrutamento
- The Heart Hospital Baylor Plano
-
Contato:
- Shelby McCoy
- Número de telefone: 469-814-3524
- E-mail: shelby.mccoy@bswhealth.org
-
Investigador principal:
- Aasim Afzal, MD
-
Temple, Texas, Estados Unidos, 76508
- Recrutamento
- Scott & White Memorial Hospital
-
Contato:
- Rohini Bagewadi
- Número de telefone: 254-724-1083
- E-mail: rohini.bagewadi@bswhealth.org
-
Investigador principal:
- Yevgeniy Khariton, MD
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84132
- Recrutamento
- University of Utah Hospital
-
Investigador principal:
- Craig Selzman, MD
-
Contato:
- Ashley Elmer
- Número de telefone: 801-585-6775
- E-mail: ashley.elmer@hsc.utah.edu
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- Recrutamento
- University of Virginia Medical Center
-
Contato:
- Tevin Jefferson
- Número de telefone: 434-982-1058
- E-mail: MFU3QX@uvahealth.org
-
Investigador principal:
- Mirnela Byku, MD
-
Richmond, Virginia, Estados Unidos, 23219
- Recrutamento
- Virginia Commonwealth University
-
Investigador principal:
- Keyur Shah, MD
-
Contato:
- Saige Dagenhart
- Número de telefone: 402-677-0237
- E-mail: Saige.Dagenhart@vcuhealth.org
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Recrutamento
- Aurora Medical Group
-
Investigador principal:
- Nasir Sulemanjee, MD
-
Contato:
- Don Lobacz
- Número de telefone: 414-649-3438
- E-mail: donald.lobacz@aah.org
-
-
-
-
Holland
-
Rotterdam, Holland, Holanda, 3015 CE
- Recrutamento
- Erasmus MC - Thoraxcenter
-
Contato:
- Nico Van Den Berg
- Número de telefone: +31-010-703-9307
- E-mail: n.berg@erasmusmc.nl
-
Investigador principal:
- Rudolf De Boer, MD
-
-
Utrecht
-
Utrecht, Utrecht, Holanda, 3584 CX
- Recrutamento
- UMC Utrecht
-
Investigador principal:
- Linda Van Laake, MD
-
Contato:
- Manon Kuikhoven
- Número de telefone: (088) 755-9432
- E-mail: m.j.kuikhoven@umcutrecht.nl
-
-
-
-
Piedmont
-
Turin, Piedmont, Itália, 10126
- Recrutamento
- A.O.U. Citta della Salute e della Scienza di Torino
-
Contato:
- Giuditta Cuccuru
- Número de telefone: +39 011 6335351
- E-mail: gcuccuru@cittadellasalute.to.it
-
Investigador principal:
- Antonino Loforte, MD
-
-
-
-
CBohmia
-
Prague, CBohmia, Tcheca, 14021
- Recrutamento
- IKEM Prague
-
Investigador principal:
- Ivan Netuka, MD
-
Contato:
- Número de telefone: +42 060 665 4220
- E-mail: martina.kucerova@ikem.cz
-
-
-
-
State of Vienna
-
Vienna, State of Vienna, Áustria, 1090
- Recrutamento
- AKH -Wien
-
Contato:
- Julia Riebandt, MD, PhD
- Número de telefone: +43 1 40400-69660
- E-mail: julia.riebandt@meduniwien.ac.at
-
Investigador principal:
- Daniel Zimpfer, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure
- LVEF ≤30% and Cardiac Index ≤ 2.5 L/min/m²
- Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL/kg/min (or <50% of predicted peak VO2 value)
- NYHA Class IIIB or NYHA Class IV
- Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months
- Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant
- Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group
Randomization Criteria:
- Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days.
- Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
- mean PAP ≥ 30 mmHg.
- The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant.
Single Arm Registry Criteria:
- Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial.
- Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
- mean PAP <30 mmHg
Exclusion Criteria:
-
Subject is < 18 years of age at the time of informed consent.
-
Dependent on IV inotrope in the last 30 days.
-
Contra-indications to HM3 LVAS or CardioMEMS HF system.
-
Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy.
-
Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter.
-
Existence of ongoing MCS.
-
Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant.
-
History of any solid organ transplant.
-
Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management.
-
Presence of an active, uncontrolled infection.
-
Complex congenital heart disease.
-
Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD.
-
History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (>1 episode) pulmonary embolism and/or deep vein thrombosis.
-
Planned VAD or Bi-VAD support prior to enrollment.
-
Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure:
- An INR ≥ 2.0 not due to anticoagulation therapy
- An eGFR < 30 mL/min/1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis.
- Biopsy proven liver cirrhosis.
- Need for chronic renal replacement therapy.
- History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 < 30% predicted.
- History of cerebrovascular disease with significant (> 80%) uncorrected internal carotid stenosis.
- Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration.
-
Any condition other than HF that could limit survival to less than 24 months.
-
Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Randomized Arm - HM3 Group
Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the HM3 group will receive the device within 14 days of randomization. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
Outros nomes:
The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.
Outros nomes:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Outros nomes:
|
|
Experimental: Randomized Arm - Control Group
Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the control group will continue their medical therapy per established heart failure guidelines. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
Outros nomes:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Outros nomes:
|
|
Experimental: Single Arm Registry
Patients who do not meet the mean PAP threshold (mean PAP <30 mmHg) and are enrolled in the single arm will continue their medical therapy per established heart failure guidelines. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
Outros nomes:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Survival at 2 years free of disabling stroke, reoperation to replace the device, or worsening HF requiring listing for urgent heart transplantation or mechanical circulatory support, enrollment into hospice, or dependence on IV inotropes
Prazo: 2 years
|
The powered primary endpoint will be analyzed at 2 years following the Com-Nougue method and will be compared between the HM3 Group (HM3 LVAD) and the Control Group (GDMT) within the Intention-to-treat (ITT) population. |
2 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of Safety Outcomes at 1-year
Prazo: 1 year
|
The powered secondary endpoint of Rate of Safety Outcomes at 1-year will be evaluated within the Intention-to-treat (ITT) population against a pre-specified performance goal. Components consist of the following:
|
1 year
|
|
Survival at 2 years
Prazo: 2 years
|
The powered secondary endpoint of survival at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. |
2 years
|
|
Quality of life score assessed with the Kansas City Cardiomyopathy Questionnaire
Prazo: 2 years
|
The secondary endpoint of Quality-of-life score at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Quality of life at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. The KCCQ scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Improvement of KCCQ by at least 10 points is considered clinically significant. |
2 years
|
|
Six-minute walk distance
Prazo: 2 years
|
The secondary endpoint of six-minute walk distance at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of six-minute walk distance at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
Hospitalizations for HF and/or Urgent HF Visit
Prazo: 2 years
|
The secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
Days alive and outside of the hospital
Prazo: 2 years
|
The secondary endpoint of days alive and outside of the hospital at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of days alive and outside of the hospital at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
All-cause hospitalizations
Prazo: 2 years
|
The secondary endpoint of all-cause hospitalizations at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all-cause hospitalizations at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
All adverse events (including all strokes) regardless of severity
Prazo: 2 years
|
The secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Finkelstein-Schoenfeld Win Ratio
Prazo: 5 years
|
The Finkelstein-Schoenfeld Win Ratio will be explored at 5 years as an additional analysis with the following hierarchy:
The Finkelstein-Schoenfeld Win Ratio will be analyzed between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the Finkelstein-Schoenfeld Win Ratio will be descriptively analyzed between the Single Arm and both the HM3 Group and Control Group of the Randomized Arm separately. |
5 years
|
|
Survival free of urgent LVAD or transplant
Prazo: 5 years
|
This additional descriptive analysis at 5-years will be performed to evaluate the proportion of patients who are alive and free of device replacement or transplant in the HM3 Group compared to the Single Arm Registry (de novo implant or transplant) |
5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Kelly O'Connell, PhD, Abbott
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
- Insuficiência cardíaca
- Gerenciamento médico
- Pressão da Artéria Pulmonar
- Dispositivo de Assistência Ventricular Esquerda (LVAD)
- Monitorização Hemodinâmica
- CardioMEMS
- Coração Mate 3 (HM3)
- Terapia Médica Dirigida por Diretrizes (GDMT)
- Dependente não inotrópico
- Insuficiência Cardíaca Avançada Ambulatorial
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ABT- CIP-10521
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .